HHS green lights six peptides, despite concerns from FDA scientists
The policy changes federal enforcement treatment for compounding; it does not amount to FDA approval of the substances.
TL;DR
- HHS announced a temporary policy allowing licensed pharmacies and physicians to compound six experimental peptides without federal enforcement action.
- The policy includes BPC-157 and TB-500, substances that FDA had previously identified as raising safety and quality concerns for compounding.
- The substances are not thereby FDA-approved, and the policy's duration and oversight implementation remain important open questions.
HHS announced a temporary policy covering six experimental peptides used in compounded preparations. STAT reported that the policy allows licensed pharmacies and physicians to compound the substances without fear of federal enforcement, while AP described the change as easing access to unproven peptides. [1] [2]
The covered group includes BPC-157 and TB-500, which have circulated in consumer-facing peptide markets. The policy concerns compounding enforcement; it is not a finding that these substances have been approved as drugs by FDA. [1] [2]
FDA's existing compounding-safety page lists BPC-157 and TB-500 among substances for which the agency has raised concerns, including immunogenicity and peptide-related impurities. FDA says it has limited or insufficient safety information for proposed human uses of these substances. [3]
STAT reported that FDA career scientists objected to the policy, citing sparse evidence about safety or effectiveness. The announcements and reports do not resolve the underlying evidence gaps, establish clinical benefit, or specify how the temporary policy will be reviewed over time. [1] [2] [3]
Why it matters
The policy changes the practical regulatory route for compounding while the FDA's stated evidence concerns remain. The distinction between enforcement discretion and approval is central to understanding what has—and has not—changed.
Editor's note
Policy coverage is supported by two independent news reports and FDA's safety page. No efficacy or consumer-use claims are made; the change is not described as drug approval.